ArticleBMC infectious diseases2022
Urogenital schistosomiasis in three different water access in the Senegal river basin: prevalence and monitoring praziquantel efficacy and re-infection levels.
Article in BMC infectious diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04635553 (Prevalence of Potential Schistosome Hybrids and Their Invasive Capacity Under Praziquantel Pressure in Northern Senegal), which is not on this map. Cited by 13 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Prevalence of Potential Schistosome Hybrids and Their Invasive Capacity Under Praziquantel Pressure in Northern Senegal
Who cites it
13 citing papers in PubMed, 2 syntheses or guidelines pooled it, 29 citations in OpenAlex.
- Prevalence of Schistosoma haematobium and Schistosoma mansoni co-infection in sub-saharan Africa: a systematic review and meta-analysis.BMC infectious diseases · 2026Pooled it
- Effects of paediatric schistosomiasis control programmes in sub-Saharan Africa: A systematic review.PloS one · 2024Pooled it
- Diagnostic Performance and Discordance of Kato-Katz Method, POC-CCA Test, and PCR in DetectingDiseases (Basel, Switzerland) · 2026Article
- Evidences That Host Genetic Background More Than the Environment Shapes the Microbiota of the Snail Bulinus truncatus, an Intermediate Host of Schistosoma Species.Molecular ecology · 2026Article
- Article
- Prevalence and risk factors of intestinal schistosomiasis among school-age children living near the Mai-Nigus irrigation dam, Tigray, northern Ethiopia: a cross-sectional study.BMC pediatrics · 2025Article
- Knowledge, attitudes and practices toward Female Genital Schistosomiasis among women living in communities along the Volta Lake in Volta Region, Ghana.PLoS neglected tropical diseases · 2025Article
- Risk factors associated with urogenital schistosomiasis: a multilevel assessment approach using an Oversampling Schistosomiasis Survey (SOS) community-based, Plateaux region, Togo 2022.BMJ public health · 2025Article
- African schistosomes in small mammal communities: Perspectives from a spatio-temporal survey in the vicinity of Lake Guiers, Senegal.PLoS neglected tropical diseases · 2024Article
- The abundance of snail hosts mediates the effects of antagonist interactions between trematodes on the transmission of human schistosomes.Infectious diseases of poverty · 2024Article
- Prevalence and associated factors of schistosomiasis among pregnant women in northern Senegal.BMC infectious diseases · 2024Article
- Exploring the Adaptation ofTropical medicine and infectious disease · 2024Article
- Schistosoma transmission: scaling-up competence from hosts to ecosystems.Trends in parasitology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 2 countries.
Funding
Abstract
backgroundUrogenital schistosomiasis is a neglected tropical disease most prevalent in sub-Saharan Africa. In the Senegal river basin, the construction of the Diama dam led to an increase and endemicity of schistosomiasis. Since 2009, praziquantel has frequently been used as preventive chemotherapy in the form of mass administration to Senegalese school-aged children without monitoring of the treatment efficacy and the prevalence after re-infection. This study aims to determine the current prevalence of urogenital schistosomiasis (caused by Schistosoma haematobium), the efficacy of praziquantel, and the re-infection rates in children from five villages with different water access.
methodsThe baseline prevalence of S. haematobium was determined in August 2020 in 777 children between 5 and 11 years old and a single dose of praziquantel (40 mg/kg) was administered to those positive. The efficacy of praziquantel and the re-infection rates were monitored 4 weeks and 7 months after treatment, respectively, in 226 children with a high intensity of infection at baseline.
resultsAt the baseline, prevalence was low among children from the village of Mbane who live close to the Lac de Guiers (38%), moderate among those from the villages of Dioundou and Khodit, which neighbor the Doue river (46%), and very high at Khodit (90.6%) and Guia (91.2%) which mainly use an irrigation canal. After treatment, the observed cure rates confirmed the efficacy of praziquantel. The lowest cure rate (88.5%) was obtained in the village using the irrigation canal, while high cure rates were obtained in those using the lake (96.5%) and the river (98%). However, high egg reduction rates (between 96.7 and 99.7%) were obtained in all the villages. The re-infection was significantly higher in the village using the canal (42.5%) than in the villages accessing the Lac de Guiers (18.3%) and the Doue river (14.8%).
conclusionPraziquantel has an impact on reducing the prevalence and intensity of urogenital schistosomiasis. However, in the Senegal river basin, S. haematobium remains a real health problem for children living in the villages near the irrigation canals, despite regular treatment, while prevalence is declining from those frequenting the river and the Lac de Guiers. Trial registration ClinicalTrials.gov, NCT04635553. Registered 19 November 2020 retrospectively registered, https://www. CLINICALTRIALS: gov/ct2/show/NCT04635553?cntry=SN&draw=2&rank=4.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.